Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia

Ming Huang Chen, Tzeon Jye Chiou, Peng Chan Lin, Jyh Pyng Gau, Hui Chi Hsu, Liang Tsai Hsiao, Jin Hwang Liu, Po Min Chen

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


This retrospective study compared outcomes for 81 chronic myeloid leukemia patients who underwent myeloablative or nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT). Sixty-five patients received myeloablative HSCT, and 16 patients received fludarabine (Fd), low-dose busulfan (Bu), and antithymocyte globulin (ATG) in nonmyeloablative HSCT. We determined overall survival (OS) and disease-free survival (DFS), as well as the occurrence of acute and chronic graft-versus-host disease (GVHD). The incidences of acute GVHD of grades II to IV were 14.0% and 18.7% for the myeloablative and nonmyeloablative groups, respectively. The incidence of chronic GVHD was significantly higher in the nonmyeloablative group (80% versus 66%). Five-year OS and DFS rates were significantly higher in nonmyeloablative group (70% for both), compared with 56% and 54%, respectively, for the myeloablative group. A univariate analysis, however, revealed a strong but statistically insignificant trend for enhanced overall OS and DFS in the nonmyeloablative group (P = .1 and .07, respectively). A multivariate analysis with the factors of treatment, age, sex, acute and chronic GVHD, and disease status at the time of transplantation revealed that both OS and DFS were significantly higher in the nonmyeloablative group than in the myeloablative group. These findings suggest that nonmyeloablative Fd/Bu/ATG treatment is at least not inferior (and quite probably superior) in terms of patient outcome compared with standard myeloablative therapy. Further larger-scale randomized clinical trials are warranted to clarify the efficacy of this treatment regimen.

Original languageEnglish
Pages (from-to)275-281
Number of pages7
JournalInternational Journal of Hematology
Issue number3
Publication statusPublished - Oct 2007
Externally publishedYes


  • Allogeneic hematopoietic stem cell transplantation
  • Chronic myeloid leukemia
  • Graft-versus-host disease
  • Myeloablative
  • Nonmyeloablative

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia'. Together they form a unique fingerprint.

Cite this